Research Article
A2ML1 Inhibits Esophageal Squamous Cell Carcinoma Progression and Serves as a Novel Prognostic Biomarker
Table 1
Association between A2ML1 protein expression and clinicopathological factors.
| Factors | Cases (n = 94) | A2ML1 protein expression | value | Low (n = 48, %) | High (n = 46, %) |
| Age | <60 years | 19 | 10 (20.83) | 9 (19.57) | 0.8784 | ≥60 years | 75 | 38 (79.17) | 37 (80.43) | |
| Sex | Female | 28 | 15 (31.25) | 13 (28.26) | 0.7514 | Male | 66 | 33 (68.75) | 33 (71.74) | |
| T stage | T1-2 | 41 | 13 (31.25) | 28 (28.26) | 0.0010 | T3-4 | 53 | 35 (68.75) | 18 (71.74) | |
| N stage | N0 | 57 | 31 (64.58) | 26 (56.52) | 0.4239 | N+ | 37 | 17 (35.42) | 20 (43.48) | |
| Differentiation | Well | 58 | 28 (58.33) | 30 (65.22) | 0.4925 | Moderate-poor | 36 | 20 (41.67) | 16 (34.78) | |
| Distant metastasis | M0 | 94 | 48 (100) | 46 (100) | | M1 | 0 | 0 (0) | 0 (0) | |
|
|
, chi-square test. A2ML1, α2-macroglobulin-like 1. |